mAbxience | Blog

The 2nd Spanish Biosimilars Conference organised by BIOSIM


The 2nd Spanish Biosimilars Conference organised by BioSim, the Spanish Association of Biosimilars, took place in Madrid on 21st February at the headquarters of the Ministry of Health, Social Services and Equality. This second conference of its kind brought together several important ministry subdivisions, medical and patient associations, healthcare professionals, specialised communication media and representatives […]

Innovator-Biosimilar Interchangeability: Safety And Efficacy Data In Clinical Practice


Interchangeability is the medical practice consisting of changing a medicinal product for another that is expected to obtain the same clinical effect in a particular clinical picture, and in any patient, at the discretion of the prescribing doctor. (1) It is therefore possible to exchange one biological medicinal product for another, as long as the […]

Biosimilar Use Position Paper Of Brazilian Society Of Clinical Oncology (SBOC)


The Brazilian Society of Oncology has just published its position paper, which includes the most important points on the approval and use of biosimilar drugs in oncology. Also included are aspects relating to their definition, nomenclature, extrapolation, interchangeability, automatic substitution, safety, efficacy and potential impact on healthcare budgets. The Society is in favour of introducing […]

Biosimilars: Lower cost, greater access


A biosimilar drug is a biological medicinal product that is developed to be highly similar to an existing biological medicinal product (“reference” or “original”).1 Its development is based on existing scientific knowledge and on an exhaustive comparability exercise with the reference biological drug. It is therefore not necessary to repeat all the clinical studies conducted with […]

What do scientific societies say about biosimilars? Rheumatology scientific societies position papers on biosimilar medicinal products


The increase in the development, marketing and availability of biological therapies has revolutionized the treatment of certain chronic and serious diseases. In this respect, biosimilar medicinal products increase biological medicinal products’ therapeutic offer by reducing health care costs and improving patient access to this type of treatments. This cost-effectiveness improvement, in some cases, has triggered […]



Regulation of similar biotherapeutic products in Latin America varies widely among different countries and many of them have yet to introduce guidance for biosimilars, Latin America is moving towards increasing standards of regulation for these products. (1, 2) During the last years ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) in Argentina, ANVISA (Agencia Nacional […]